Including Funding rounds, Bull / Bear thesis, Stock + earnings, Roster changes, Patents, News, and Open roles.
Already subscribed? Sign in →
NeuroPace reported Q1 2026 revenue of $22.1 million, with RNS System revenue of $21.7 million, representing 19.5% year-over-year growth (20.1% excluding divested DIXI Medical). GAAP net loss was $6.7 million, compared to $6.6 million in Q1 2025; however, adjusted EBITDA loss improved to ($3.3) million from ($4.1) million. GAAP gross margin was 81.8%; non-GAAP gross margin 82.5%, down 110 basis points from Q1 2025 which included a one-time 120 basis point inventory revaluation benefit. Operating expenses increased to $23.6 million due to scaling commercial activities and personnel costs. The company raised full-year 2026 guidance to $99–101 million revenue (from $98–100 million), assuming 21–23% RNS growth, and improved adjusted EBITDA guidance to ($8.5)–($9.5) million. The NAUTILUS PMA-Supplement for IGE indication expansion completed mid-cycle FDA review and is expected for mid-2026 approval. Active prescribers, accounts, and patient pipeline reached all-time highs.
$99–101 million full-year 2026 revenue; 21–23% underlying RNS growth; adjusted EBITDA loss ($8.5)–($9.5) million
No articles ingested yet for NeuroPace. Once the hourly news pipeline is live, every article the classifier tags as mentioning this company appears here with its one-line AI summary and sentiment.
The first and only FDA-approved closed-loop brain stimulation device for drug-resistant focal epilepsy. A skull-mounted neurostimulator continuously monitors electrocorticographic activity via implanted cortical leads; when it detects pre-seizure patterns it delivers a brief burst of electrical stimulation to interrupt the ictal event before clinical symptoms emerge. Over several years of use, patients show progressively greater seizure reduction as the device learns individual seizure signatures.
We don't have a live feed for this company's ATS. Their careers page has every open role.
View all careers ↗